These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 17075319)

  • 1. Ten years of experience with weekly chemotherapy in metastatic breast cancer patients: multivariate analysis of prognostic factors.
    Nisticò C; Cuppone F; Bria E; Fornier M; Giannarelli D; Mottolese M; Novelli F; Natoli G; Cognetti F; Terzoli E
    Anticancer Drugs; 2006 Nov; 17(10):1193-200. PubMed ID: 17075319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
    Martín M; Rodríguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munárriz B; Rodríguez CA; Crespo C; de Alava E; López García-Asenjo JA; Guitián MD; Almenar S; González-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Seguí MA; Mayordomo JI; Antón A; Baena JM; Plazaola A; Modolell A; Pelegrí A; Mel JR; Aranda E; Adrover E; Alvarez JV; García Puche JL; Sánchez-Rovira P; Gonzalez S; López-Vega JM;
    J Natl Cancer Inst; 2008 Jun; 100(11):805-14. PubMed ID: 18505968
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metastatic breast cancer with liver metastases: a registry analysis of clinicopathologic, management and outcome characteristics of 500 women.
    Pentheroudakis G; Fountzilas G; Bafaloukos D; Koutsoukou V; Pectasides D; Skarlos D; Samantas E; Kalofonos HP; Gogas H; Pavlidis N
    Breast Cancer Res Treat; 2006 Jun; 97(3):237-44. PubMed ID: 16322882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survival of metastatic breast carcinoma patients over a 20-year period: a retrospective analysis based on individual patient data from six consecutive studies.
    Gennari A; Conte P; Rosso R; Orlandini C; Bruzzi P
    Cancer; 2005 Oct; 104(8):1742-50. PubMed ID: 16149088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Weekly epirubicin and paclitaxel with granulocyte colony-stimulating factor support in previously untreated metastatic breast cancer patients: a phase II study.
    Nisticò C; Bria E; Cuppone F; Fornier M; Sperduti I; Carpino A; Pace A; Cognetti F; Terzoli E
    Anticancer Drugs; 2007 Jul; 18(6):687-92. PubMed ID: 17762397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic factors for metastatic urothelial carcinoma treated with cisplatin and 5-fluorouracil-based regimens.
    Lin CC; Hsu CH; Huang CY; Tsai YC; Huang KH; Cheng AL; Pu YS
    Urology; 2007 Mar; 69(3):479-84. PubMed ID: 17382149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response to second-line chemotherapy in patients with metastatic breast carcinoma previously responsive to first-line treatment: prognostic factors.
    Brun B; Benchalal M; Lebas C; Piedbois P; Lin M; Lebourgeois JP
    Cancer; 1997 Jun; 79(11):2137-46. PubMed ID: 9179060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survival of patients with metastatic breast carcinoma: importance of prognostic markers of the primary tumor.
    Chang J; Clark GM; Allred DC; Mohsin S; Chamness G; Elledge RM
    Cancer; 2003 Feb; 97(3):545-53. PubMed ID: 12548595
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum epidermal growth factor receptor/HER-2 predicts poor survival in patients with metastatic breast cancer.
    Souder C; Leitzel K; Ali SM; Demers L; Evans DB; Chaudri-Ross HA; Hackl W; Hamer P; Carney W; Lipton A
    Cancer; 2006 Nov; 107(10):2337-45. PubMed ID: 17048231
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical characteristics and prognostic factors of female breast cancer patients with 10 or more positive lymph nodes: a report of 128 patients].
    Guan Y; Xu BH; Li Q; Zhang P; Zhao LM; Yuan P; Wang JY
    Zhonghua Yi Xue Za Zhi; 2008 Jan; 88(2):77-81. PubMed ID: 18353207
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic and predictive effects of immunohistochemical factors in high-risk primary breast cancer patients.
    Kröger N; Milde-Langosch K; Riethdorf S; Schmoor C; Schumacher M; Zander AR; Löning T
    Clin Cancer Res; 2006 Jan; 12(1):159-68. PubMed ID: 16397038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival impact of integrative cancer care in advanced metastatic breast cancer.
    Block KI; Gyllenhaal C; Tripathy D; Freels S; Mead MN; Block PB; Steinmann WC; Newman RA; Shoham J
    Breast J; 2009; 15(4):357-66. PubMed ID: 19470134
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Initially metastatic breast carcinoma has a distinct disease pattern but an equivalent outcome compared with recurrent metastatic breast carcinoma.
    Jimeno A; Amador ML; González-Cortijo L; Tornamira MV; Ropero S; Valentín V; Hornedo J; Cortés-Funes H; Colomer R
    Cancer; 2004 May; 100(9):1833-42. PubMed ID: 15112263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive and prognostic values of tau and ERCC1 in advanced breast cancer patients treated with paclitaxel and cisplatin.
    Shao YY; Kuo KT; Hu FC; Lu YS; Huang CS; Liau JY; Lee WC; Hsu C; Kuo WH; Chang KJ; Lin CH; Cheng AL
    Jpn J Clin Oncol; 2010 Apr; 40(4):286-93. PubMed ID: 20085902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fifteen-year trends in metastatic breast cancer survival in Greece.
    Dafni U; Grimani I; Xyrafas A; Eleftheraki AG; Fountzilas G
    Breast Cancer Res Treat; 2010 Feb; 119(3):621-31. PubMed ID: 19915976
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of changes in CA 15-3 serum levels during chemotherapy in metastatic breast cancer patients.
    Tampellini M; Berruti A; Bitossi R; Gorzegno G; Alabiso I; Bottini A; Farris A; Donadio M; Sarobba MG; Manzin E; Durando A; Defabiani E; De Matteis A; Ardine M; Castiglione F; Danese S; Bertone E; Alabiso O; Massobrio M; Dogliotti L
    Breast Cancer Res Treat; 2006 Aug; 98(3):241-8. PubMed ID: 16670941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Weekly administration of bendamustine as salvage therapy in metastatic breast cancer: final results of a phase II study.
    Eichbaum MH; Schuetz F; Khbeis T; Lauschner I; Foerster F; Sohn C; Schneeweiss A
    Anticancer Drugs; 2007 Sep; 18(8):963-8. PubMed ID: 17667603
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic factors for survival of patients with advanced gastric cancer treated with cisplatin-based chemotherapy.
    Kim JG; Ryoo BY; Park YH; Kim BS; Kim TY; Im YH; Kang YK
    Cancer Chemother Pharmacol; 2008 Feb; 61(2):301-7. PubMed ID: 17429626
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic factors in metastatic breast cancer patients obtaining objective response or disease stabilization after first-line chemotherapy with epirubicin. Evidence for a positive effect of maintenance hormonal therapy on overall survival.
    Berruti A; Zola P; Buniva T; Baù MG; Farris A; Sarobba MG; Bottini A; Tampellini M; Durando A; Destefanis M; Monzeglio C; Moro G; Sussio M; Perroni D; Dogliotti L
    Anticancer Res; 1997; 17(4A):2763-8. PubMed ID: 9252712
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.